1. 4CPS-215 Access to 'fondo AIFA 5%' as an instrument supporting the sustainability in a shared clinical management of rare and difficult-to-treat diseases. (March 2019) Authors: Valinotti, G; Scaldaferri, M; Tonelli, M; Crosasso, P; Chiappetta, MR; Cattel, F Journal: European journal of hospital pharmacy Issue: Volume 26(2019)Supplement 1 Page Start: A169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CP-100 Pegylated interferon ALFA 2-A in myeloproliferative neoplasms. (25th February 2017) Authors: Scaldaferri, M; Varese, A; Tonelli, M; Barilà, D; Bianco, A; Valinotti, G; Caiazza, E; Martinetto, D; Ferroni, M; Cattel, F Journal: European journal of hospital pharmacy Issue: Volume 24(2017)Supplement 1 Page Start: A44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CP-134 Analysys of therapeutic response and tolerability in patients treated with crizotinib in ALK positive NSCLC. (14th February 2016) Authors: Tonelli, M; Scaldaferri, M; Barilà, D; Bianco, A; Ferroni, M; Valinotti, G; Caiazza, E; Bordignon, S; Martinetto, D; Cattel, F Journal: European journal of hospital pharmacy Issue: Volume 23(2016)Supplement 1 Page Start: A59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗